A selective and sensitive stability-Indicating HPLC method for the validated assay of etoposide from commercial dosage form and polymeric tubular nanocarriers
- 1 May 2016
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 124, 382-389
Abstract
No abstract availableKeywords
Funding Information
- Scientific and Technological Research Council of Turkey (113S201)
This publication has 26 references indexed in Scilit:
- Nanomedicines for targeted delivery of etoposide to non-small cell lung cancer using transferrin functionalized nanoparticlesRSC Advances, 2015
- Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposideJournal of Biosciences, 2014
- Reformulation of etoposide with solubility-enhancing rubusosideInternational Journal of Pharmaceutics, 2012
- Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHX) based nanoparticles for targeted cancer therapyEuropean Journal of Pharmaceutical Sciences, 2011
- Etoposide-loaded biodegradable amphiphilic methoxy (poly ethylene glycol) and poly (epsilon caprolactone) copolymeric micelles as drug delivery vehicle for cancer therapyDrug Delivery, 2010
- Cellular response to etoposide treatmentCancer Letters, 2007
- Etoposide, Topoisomerase II and CancerCurrent Medicinal Chemistry - Anti-Cancer Agents, 2005
- Etoposide-loaded nanoparticles made from glyceride lipids: Formulation, characterization, in vitro drug release, and stability evaluationAAPS PharmSciTech, 2005
- Nanotechnology: challenging the limit of creativity in targeted drug deliveryAdvanced Drug Delivery Reviews, 2004
- Etoposide: four decades of development of a topoisomerase II inhibitorEuropean Journal of Cancer, 1998